Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 8/2016

01-08-2016

Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome

Auteurs: Tae Heon Kim, Myung-Soo Choo, Young-Joo Kim, Hyein Koh, Kyu-Sung Lee

Gepubliceerd in: Quality of Life Research | Uitgave 8/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To evaluate persistence and compliance for patients receiving antimuscarinics for overactive bladder (OAB), and to assess patient-reported outcomes (PROs) according to persistence and compliance.

Methods

This was a 24-week, multicenter, prospective, observational study that included 952 OAB patients who had newly started antimuscarinics. Patients aged ≥18 years with a total OAB Symptom Score (OABSS) ≥3 and an urgency score of OABSS ≥2 were eligible for the study. Drug persistence and compliance were evaluated at 4, 12, and 24 weeks. Changes in scores on PROs were compared between groups (persistence vs. non-persistence and compliance vs. non-compliance) after 24 weeks. Factors contributing to persistence were examined using multivariate logistic regression.

Results

After 24 weeks, 56.8 % of patients remained on treatment. The persistence rates were 85.6 and 71.4 % after 4 and 12 weeks, respectively. The compliance rates were 75.6, 53.8, and 34.3 % after 4, 12, and 24 weeks, respectively. Patients who were persistent in taking antimuscarinics resulted in significant improvements in OABSS and OAB questionnaire short form score compared with those who were non-persistent (all p < 0.05). Changes from baseline in OABSS (p = 0.735) and the EuroQoL five-dimensions score (p = 0.384) were not significantly different between compliant and non-compliant groups. Predictors of high persistence included older age (OR 1.017, p = 0.007) and dry OAB (OR 1.422, p = 0.013).

Conclusions

Patients who were persistent with antimuscarinics showed significant improvements in PROs compared to those who were non-persistent.
vorige artikel Trajectories and associated factors of quality of life, global outcome, and post-concussion symptoms in the first year following mild traumatic brain injury
volgende artikel Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice
Literatuur
1.
Abrams, P., Cardozo, L., Fall, M., Griffiths, D., Rosier, P., Ulmsten, U., et al. (2002). The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourology and Urodynamics, 21(2), 167–178.CrossRefPubMed
2.
Haylen, B. T., de Ridder, D., Freeman, R. M., Swift, S. E., Berghmans, B., Lee, J., et al. (2010). An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. International Urogynecology Journal, 21(1), 5–26.CrossRefPubMed
3.
Irwin, D. E., Milsom, I., Hunskaar, S., Reilly, K., Kopp, Z., Herschorn, S., Coyne, K., Kelleher, C., Hampel, C., Artibani, W., & Abrams, P. (2006). Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European Urology, 50(6), 1306–1314; discussion 1314-1305.
4.
Lee, Y. S., Lee, K. S., Jung, J. H., Han, D. H., Oh, S. J., Seo, J. T., et al. (2011). Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. World Journal of Urology, 29(2), 185–190.CrossRefPubMed
5.
Kim, T. H., Han, D. H., & Lee, K. S. (2014). The prevalence of lower urinary tract symptoms in korean men aged 40 years or older: A population-based survey. International Neurourology Journal, 18(3), 126–132.CrossRefPubMedPubMedCentral
6.
Coyne, K. S., Sexton, C. C., Irwin, D. E., Kopp, Z. S., Kelleher, C. J., & Milsom, I. (2008). The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU International, 101(11), 1388–1395.CrossRefPubMed
7.
Coyne, K. S., Sexton, C. C., Kopp, Z. S., Ebel-Bitoun, C., Milsom, I., & Chapple, C. (2011). The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: Results from EpiLUTS. BJU International, 108(9), 1459–1471.CrossRefPubMed
8.
Lee, Y. I., Kim, J. W., Bae, S. R., Paick, S. H., Kim, K. W., Kim, H. G., et al. (2013). Effect of urgency symptoms on the risk of depression in community-dwelling elderly men. Korean Journal of Urology, 54(11), 762–766.CrossRefPubMedPubMedCentral
9.
Park, H. K., Chang, S., Palmer, M. H., Kim, I., & Choi, H. (2015). Assessment of the impact of male urinary incontinence on health-related quality of life: A population based study. Luts-Lower Urinary Tract Symptoms, 7(1), 22–26.CrossRef
10.
Andersson, K. E., Chapple, C. R., Cardozo, L., Cruz, F., Hashim, H., Michel, M. C., et al. (2009). Pharmacological treatment of overactive bladder: Report from the International Consultation on Incontinence. Current Opinion in Urology, 19(4), 380–394.CrossRefPubMed
11.
Haab, F., Cardozo, L., Chapple, C., Ridder, A. M., & Solifenacin Study, G. (2005). Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. European Urology, 47(3), 376–384.CrossRefPubMed
12.
Sexton, C. C., Notte, S. M., Maroulis, C., Dmochowski, R. R., Cardozo, L., Subramanian, D., & Coyne, K. S. (2011). Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: A systematic review of the literature. International Journal of Clinical Practice, 65(5), 567–585.CrossRefPubMed
13.
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008). Medication compliance and persistence: Terminology and definitions. Value Health, 11(1), 44–47.CrossRefPubMed
14.
Yu, Y. F., Nichol, M. B., Yu, A. P., & Ahn, J. (2005). Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program. Value Health, 8(4), 495–505.CrossRefPubMed
15.
Shaya, F. T., Blume, S., Gu, A., Zyczynski, T., & Jumadilova, Z. (2005). Persistence with overactive bladder pharmacotherapy in a Medicaid population. American Journal of Managed Care, 11(4 Suppl), S121–S129.PubMed
16.
Wagg, A., Compion, G., Fahey, A., & Siddiqui, E. (2012). Persistence with prescribed antimuscarinic therapy for overactive bladder: A UK experience. BJU International, 110(11), 1767–1774.CrossRefPubMed
17.
Homma, Y., Yoshida, M., Seki, N., Yokoyama, O., Kakizaki, H., Gotoh, M., et al. (2006). Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology, 68(2), 318–323.CrossRefPubMed
18.
Rammstedt, B., & John, O. (2007). Measuring personality in one minute or less: A 10-item short version of the Big Five Inventory in English and German. Journal of Research in Personality, 41(1), 203–212.CrossRef
19.
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009). Medication adherence: Its importance in cardiovascular outcomes. Circulation, 119(23), 3028–3035.CrossRefPubMed
20.
EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef
21.
Coyne, K., Revicki, D., Hunt, T., Corey, R., Stewart, W., Bentkover, J., et al. (2002). Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q. Quality of Life Research, 11(6), 563–574.CrossRefPubMed
22.
Oh, S. J., Son, H., Kim, S. W., Lee, K. S., Choo, M. S., Kim, S. O., & Lee, M. S. (2012). Psychometric properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population. International Neurourology Journal, 16(2), 77–85.CrossRefPubMedPubMedCentral
23.
Daniel, W. (1999). Biostatistics: A foundation for analysis in the health sciences. New York: Wiley.
24.
Hosmer, D, Jr, & Lemeshow, S. (1989). Applied logistic regression. New York: Wiley.
25.
Krueger, K. P., Berger, B. A., & Felkey, B. (2005). Medication adherence and persistence: a comprehensive review. Advances in Therapy, 22(4), 313–356.CrossRefPubMed
26.
Veenboer, P. W., & Bosch, J. L. (2014). Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. Journal of Urology, 191(4), 1003–1008.CrossRefPubMed
27.
Sears, C. L., Lewis, C., Noel, K., Albright, T. S., & Fischer, J. R. (2010). Overactive bladder medication adherence when medication is free to patients. Journal of Urology, 183(3), 1077–1081.CrossRefPubMed
28.
D’Souza, A. O., Smith, M. J., Miller, L. A., Doyle, J., & Ariely, R. (2008). Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. Journal of Managed Care Pharmacy, 14(3), 291–301.CrossRefPubMed
29.
Yeaw, J., Benner, J. S., Walt, J. G., Sian, S., & Smith, D. B. (2009). Comparing adherence and persistence across 6 chronic medication classes. Journal of Managed Care Pharmacy, 15(9), 728–740.CrossRefPubMed
30.
Athanasopoulos, A., & Giannitsas, K. (2011). An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Advances in Therapy, 2011, 820816.
Metagegevens
Titel
Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome
Auteurs
Tae Heon Kim
Myung-Soo Choo
Young-Joo Kim
Hyein Koh
Kyu-Sung Lee
Publicatiedatum
01-08-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 8/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1216-z

Andere artikelen Uitgave 8/2016

Quality of Life Research 8/2016 Naar de uitgave

OriginalPaper

Home but still engaged: participation in social activities among the homebound

OriginalPaper

Factors influencing psychosocial adjustment and quality of life in Parkinson patients and informal caregivers

OriginalPaper

Impact of nine chronic conditions for US adults aged 65 years and older: an application of a hybrid estimator of quality-adjusted life years throughout remainder of lifetime

Brief Communication

The effect of response option order on self-rated health: a replication study

OriginalPaper

Is health-related quality of life between 90 and 180 days following stroke associated with long-term unmet needs?

OriginalPaper

Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice